You are here: Home » Companies » News
Business Standard

Lupin gets Establishment Inspection Report from FDA for Aurangabad facility

The facility was inspected by the US Food and Drug Administration

Press Trust of India  |  New Delhi 


Drug firm Lupin on Monday said it has received an Establishment Inspection Report (EIR) from the US health regulator for its Aurangabad facility in Maharashtra.

The facility was inspected by the (USFDA) between May 6-15, 2019, Lupin said in a filing.

Lupin said its Aurangabad facility is involved in the manufacturing of oral solid dosage, oral liquid and powder for oral suspension products for the US Market, WHO/Global Institution markets and Indian market.

"Lupin is committed to adherence and full compliance with current good manufacturing practice (cGMP) regulations and all other applicable regulatory requirements at our manufacturing sites. We are very happy to receive the EIR for our Aurangabad facility marking the satisfactory closure of the inspection," Lupin Managing Director Nilesh Gupta said.

The issues an EIR to an establishment that is the subject of an FDA or FDA-contracted inspection when the agency decides to close the inspection.

Lupin's shares were trading 1.05 per cent lower at Rs 757.75 apiece on the

First Published: Mon, August 05 2019. 10:50 IST